Recently, the R&D 100 Awards, widely known as the "Oscar of Innovation," announced their 2026 winners. The CybeRay Pro intelligent non-invasive radiosurgery treatment product, selected in the award list, was manufactured by OUR United Corporation's Changchun Innovation Industrial Base in Changchun New Area. This marks the first time since the award's establishment in 1963 that a company from the Chinese mainland has won the honor as the principal submitting organization in the field of large-scale medical equipment.

CybRay Pro, the award-winning product, is the world's first real-time image-guided gamma radiosurgery platform approved by the U.S. Food and Drug Administration (FDA), enabling sub‑millimeter precise ablation treatment. The equipment incorporates three core technologies: real-time intra-fraction image guidance, dynamic non-coplanar arc delivery, and rotating focus. It can track tumor displacement caused by breathing and heartbeat in real time, precisely targeting lesions while maximizing protection for normal organs and tissues. Comparative verification by internationally authoritative institutions proves that the equipment can significantly reduce radiation doses to organs at risk, reduce average treatment time to approximately 30 minutes, and achieve globally leading performance in multiple key indicators.

As the only medical device enterprise from the Chinese mainland to lead an award submission among this year's 100 winning projects, OUR United Corporation is also the first enterprise to receive the award for large-scale medical equipment since the award was established. Its product, CybeRay Pro, represents a major innovation in large-scale and complex systems. It spans multiple disciplines including precision machine, image-guided navigation, and radiation physics, characterized by high technical barriers and substantial R&D challenges.

This award marks a major leap for China's high-end radiotherapy equipment from a homegrown substitution to a global pacesetter.

Source: Jilin Release  Editor: Liu Jiadi